Last reviewed · How we verify
ALBUMIN HUMAN — Competitive Intelligence Brief
marketed
Recombinant protein
Live · refreshed every 30 min
Target snapshot
ALBUMIN HUMAN (ALBUMIN HUMAN). Human Albumin 25% contributes to plasma colloid oncotic pressure and transports various substances, stabilizing blood volume.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ALBUMIN HUMAN TARGET | ALBUMIN HUMAN | marketed | 1997-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ALBUMIN HUMAN CI watch — RSS
- ALBUMIN HUMAN CI watch — Atom
- ALBUMIN HUMAN CI watch — JSON
- ALBUMIN HUMAN alone — RSS
Cite this brief
Drug Landscape (2026). ALBUMIN HUMAN — Competitive Intelligence Brief. https://druglandscape.com/ci/albumin-human. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing